INNOVATIVE TRANSFORMATIONS OF THE VALUE CHAIN OF PHARMACEUTICAL ENTERPRISES
The research is devoted to the substantiation of the necessity of innovative transformations of the value chain of pharmaceutical enterprises. The current state of the international pharmaceutical market and its development scenarios developed by the WTO were analyzed, taking into account the changes caused by the COVID-19 coronavirus pandemic. The typology of value chains is considered and their element-by-element characteristics are given. A new, modern model of interaction in the chain of value creation of products is proposed. The substantiation of efficiency of creation of such chains is given. Based on the correlation analysis, the presence of a linear relationship between the indicators of Pharmaceutical R&D Spend and Revenue was established. To maximize the effect of R&D costs, pharmaceutical companies are recommended to carry out innovative transformations of the value chain, involving external manufacturers of high-tech devices, applications, etc..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
---|---|
Enthalten in: |
Економіка та суспільство - (2021), 24 |
Sprache: |
Englisch ; Ukrainisch |
---|
Beteiligte Personen: |
Kateryna Kopishynska [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
Business |
---|
doi: |
10.32782/2524-0072/2021-24-42 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ028300149 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ028300149 | ||
003 | DE-627 | ||
005 | 20230503061528.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230226s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.32782/2524-0072/2021-24-42 |2 doi | |
035 | |a (DE-627)DOAJ028300149 | ||
035 | |a (DE-599)DOAJ0fad4298469b458284e387ba7a836f09 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng |a ukr | ||
050 | 0 | |a HB71-74 | |
050 | 0 | |a HF5001-6182 | |
100 | 0 | |a Kateryna Kopishynska |e verfasserin |4 aut | |
245 | 1 | 0 | |a INNOVATIVE TRANSFORMATIONS OF THE VALUE CHAIN OF PHARMACEUTICAL ENTERPRISES |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a The research is devoted to the substantiation of the necessity of innovative transformations of the value chain of pharmaceutical enterprises. The current state of the international pharmaceutical market and its development scenarios developed by the WTO were analyzed, taking into account the changes caused by the COVID-19 coronavirus pandemic. The typology of value chains is considered and their element-by-element characteristics are given. A new, modern model of interaction in the chain of value creation of products is proposed. The substantiation of efficiency of creation of such chains is given. Based on the correlation analysis, the presence of a linear relationship between the indicators of Pharmaceutical R&D Spend and Revenue was established. To maximize the effect of R&D costs, pharmaceutical companies are recommended to carry out innovative transformations of the value chain, involving external manufacturers of high-tech devices, applications, etc. | ||
650 | 4 | |a value chain | |
650 | 4 | |a innovation | |
650 | 4 | |a pharmaceutical enterprise | |
650 | 4 | |a COVID-19 | |
653 | 0 | |a Economics as a science | |
653 | 0 | |a Business | |
700 | 0 | |a Kateryna Zinchenko |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Економіка та суспільство |d Helvetica Publishing House, 2022 |g (2021), 24 |w (DE-627)DOAJ078598788 |x 25240072 |7 nnns |
773 | 1 | 8 | |g year:2021 |g number:24 |
856 | 4 | 0 | |u https://doi.org/10.32782/2524-0072/2021-24-42 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/0fad4298469b458284e387ba7a836f09 |z kostenfrei |
856 | 4 | 0 | |u http://economyandsociety.in.ua/index.php/journal/article/view/220 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2524-0072 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2021 |e 24 |